WFDC2 and ovarian cancer: Previously, we reported that a four-biomarker panel comprising CA125, HE4, CA72-4 and MMP-7 showed strong diagnostic performance and significant improvement over the use of CA125 alone in distinguishing patients with early stage ovarian cancer from healthy women [49].